Modality
Degrader
MOA
IL-23i
Target
CD20
Pathway
Hedgehog
ObesityCSU
Development Pipeline
Preclinical
~Feb 2012
→ ~May 2013
Phase 1
~Aug 2013
→ ~Nov 2014
Phase 2
~Feb 2015
→ ~May 2016
Phase 3
~Aug 2016
→ ~Nov 2017
NDA/BLA
Feb 2018
→ Sep 2028
NDA/BLACurrent
NCT07786782
723 pts·CSU
2018-02→2028-09·Completed
723 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-212.5y awayPh3 Readout· CSU
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2028-09-21 · 2.5y away
CSU
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07786782 | NDA/BLA | CSU | Completed | 723 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | CFTR | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 |